ECLIPSE: Lu-177-PSMA-I&T for metastic Castration-Resistant Prostate Cancer
metastatic Castration-Resistant Prostate Cancer (mCRPC)
Intervention Type: Drug
Intervention Name: Lu-177-PSMA-I&T
Intervention Description: Intravenous radioligand therapy
Curium reference number
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
The purpose of this study is to compare the safety and efficacy of 177Lu-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer.